Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2000 2
2001 5
2002 1
2003 6
2004 4
2005 5
2006 5
2007 9
2008 7
2009 2
2011 8
2012 8
2013 6
2014 3
2015 1
2016 4
2017 2
2019 1
2020 3
2021 3
2023 3
2024 3
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Horwitz SM, et al. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Blood Adv. 2021. PMID: 34507350 Free PMC article. Clinical Trial.
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting 4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30-expressing …
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting 4 months (ORR4; primary endpoin …
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK, Liu N, DerSarkissian M, Chang R, Ye M, Duh MS, Surinach A, Fanale M, Yu KS. Barta SK, et al. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e21-e32.e4. doi: 10.1016/j.clml.2023.10.001. Epub 2023 Oct 11. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37919137 Free article. Clinical Trial.
In ALCANZA, patients with pcALCLs or CD30-positive MF randomized to brentuximab vedotin (BV) vs. physician's choice of methotrexate or bexarotene had significantly improved outcomes, including higher objective response rates (ORR) lasting 4 months (ORR4), as well as longe …
In ALCANZA, patients with pcALCLs or CD30-positive MF randomized to brentuximab vedotin (BV) vs. physician's choice of methotrexate or be …
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Duvic M, et al. Arch Dermatol. 2001 May;137(5):581-93. Arch Dermatol. 2001. PMID: 11346336 Clinical Trial.
PATIENTS: Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were intolerant of) treatment or had reached at least a 6-month response plateau under at least 2 forms of prior therapy (median of 3.5 prior thera …
PATIENTS: Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were in …
Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.
Sanagawa A, Hayakawa T, Yamamoto A, Hotta Y, Furukawa-Hibi Y, Morita A. Sanagawa A, et al. Drugs R D. 2024 Jun;24(2):227-238. doi: 10.1007/s40268-024-00465-7. Epub 2024 Jun 13. Drugs R D. 2024. PMID: 38871976 Free PMC article. Clinical Trial.
We previously demonstrated the severity of bexarotene-associated hypertriglyceridemia and the need for bexarotene dose reduction for patients with cutaneous T-cell lymphoma and high body mass index (BMI); however, high BMI does not affect the efficacy of combined …
We previously demonstrated the severity of bexarotene-associated hypertriglyceridemia and the need for bexarotene dose reducti …
A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, van De Kerkhof PC. Smit JV, et al. J Am Acad Dermatol. 2004 Aug;51(2):249-56. doi: 10.1016/j.jaad.2002.08.001. J Am Acad Dermatol. 2004. PMID: 15280844 Clinical Trial.
In psoriasis, a common retinoid-sensitive disease, no data are available on bexarotene treatment. OBJECTIVE: In this phase II study we investigated the safety, tolerability, and effectiveness of bexarotene in psoriasis at doses of 0.5 to 3.0 mg/kg/day. ...CONCLUSION …
In psoriasis, a common retinoid-sensitive disease, no data are available on bexarotene treatment. OBJECTIVE: In this phase II study w …
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M. Whittaker S, et al. Br J Dermatol. 2012 Sep;167(3):678-87. doi: 10.1111/j.1365-2133.2012.11156.x. Br J Dermatol. 2012. PMID: 22924950 Clinical Trial.
OBJECTIVE: To assess disease response and to compare the response rates of patients treated with PUVA alone or PUVA and bexarotene. METHODS: EORTC 21011 (NCT 00056056) was a randomized phase III study comparing combined bexarotene (Targretin( ) ) and PUVA vs. ...How …
OBJECTIVE: To assess disease response and to compare the response rates of patients treated with PUVA alone or PUVA and bexarotene. M …
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. doi: 10.1158/1078-0432.CCR-06-1836. Clin Cancer Res. 2007. PMID: 17363535 Clinical Trial.
Twelve patients were enrolled, and 10 were evaluable. Bexarotene treatment was well tolerated. There was nonlinear correlation between plasma and tumor bexarotene concentrations (r(2) = 0.77). ...The cases with multiple biomarker changes had high tumor bexarotene …
Twelve patients were enrolled, and 10 were evaluable. Bexarotene treatment was well tolerated. There was nonlinear correlation betwee …
The treatment of cutaneous T-cell lymphoma with a novel retinoid.
Heald P. Heald P. Clin Lymphoma. 2000 Nov;1 Suppl 1:S45-9. doi: 10.3816/clm.2000.s.009. Clin Lymphoma. 2000. PMID: 11707864 Free article. Review.
The clinical experience with bexarotene for cutaneous T-cell lymphoma (CTCL) at our center is reviewed here. Disease activity assessment was monitored every 4 weeks in all patients. ...No new lesions were noted in patients on high-dose bexarotene. Self-assessments a …
The clinical experience with bexarotene for cutaneous T-cell lymphoma (CTCL) at our center is reviewed here. Disease activity assessm …
Phase II clinical trial of bexarotene gel 1% in psoriasis.
Breneman D, Sheth P, Berger V, Naini V, Stevens V. Breneman D, et al. J Drugs Dermatol. 2007 May;6(5):501-6. J Drugs Dermatol. 2007. PMID: 17679184 Clinical Trial.
Patients applied bexarotene gel 1%, using an application frequency escalation regimen, starting at once every other day and increasing to 4 times daily as tolerated and beneficial for up to 24 weeks. ...Adverse events occurred primarily at application sites and were mild o …
Patients applied bexarotene gel 1%, using an application frequency escalation regimen, starting at once every other day and increasin …
Bexarotene and erlotinib for aerodigestive tract cancer.
Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E. Dragnev KH, et al. J Clin Oncol. 2005 Dec 1;23(34):8757-64. doi: 10.1200/JCO.2005.01.9521. J Clin Oncol. 2005. PMID: 16314636 Clinical Trial.
PURPOSE: The epidermal growth factor receptor (EGFR) and cyclin D1 are overexpressed in lung carcinogenesis. The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, …
PURPOSE: The epidermal growth factor receptor (EGFR) and cyclin D1 are overexpressed in lung carcinogenesis. The rexinoid, bexarotene …
83 results